Plain-English translation of NCT05071937 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination of two medications— and —to see if they work better together against ovarian cancer that has come back. works by slowing down cancer cell growth, while works by damaging cancer cells' ability to repair themselves. Neither medication is currently FDA-approved for ovarian cancer, so this research aims to find out if this pairing could be a new treatment option.
Many patients with recurrent ovarian cancer need new treatment options, especially those whose cancer has already been treated with similar medications. This trial exists to see if combining these two drugs in a new way might help patients whose cancer has returned.
You likely qualify if…
You likely don't qualify if…
You would take two pills by mouth every day as part of a 28-day treatment cycle. You'll take (48 mg daily) and (0.75 mg daily) at the same time. Throughout the study, you'll have regular visits to check your health, have blood tests to monitor how the medications are working, and have scans to measure whether your cancer is responding to the treatment. The study involves about 33 patients total, and your doctors will watch carefully for any side effects.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
United States